Date Filed | Type | Description |
10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
10/10/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
10/10/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
10/02/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
09/29/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
09/26/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
09/26/2023 |
SC 13D/A
| Anson Funds Management LP reports a 13% stake in MEI Pharma, Inc. |
09/26/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/08/2023 |
SC 13D/A
| Anson Funds Management LP reports a 9.9% stake in MEI Pharma, Inc. |
08/04/2023 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
07/19/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
07/17/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
07/17/2023 |
SC 13D/A
| Anson Funds Management LP reports a 9.9% stake in MEI Pharma, Inc. |
07/17/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
05/30/2023 |
3
| Anson Funds Management LP (10% Owner) has filed a Form 3 on MEI Pharma, Inc. |
05/30/2023 |
SC 13D
| Anson Funds Management LP reports a 9.9% stake in MEI Pharma Inc. |
05/19/2023 |
13F-HR/A
| Form 13F-HR/A - Quarterly report filed by institutional managers, Holdings: [Amend] |
05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/02/2023 |
SC 13D/A
| Anson Funds Management LP reports a 6.2% stake in Nano Dimension Ltd. |
03/10/2023 |
SC 13D
| Anson Funds Management LP reports a 5.1% stake in Nano Dimension Ltd. |
02/14/2023 |
SC 13G/A
| Anson Funds Management LP reports a 9.9% stake in LogicMark Inc. |
02/14/2023 |
SC 13G
| Anson Funds Management LP reports a 9.9% stake in View, INC. |
02/14/2023 |
SC 13G/A
| Anson Funds Management LP reports a 0% stake in Appreciate Holdings Inc. |
02/14/2023 |
SC 13G
| Anson Funds Management LP reports a 8% stake in MEI PHARMA, INC. |
02/14/2023 |
SC 13G/A
| Anson Funds Management LP reports a 0% stake in Model Performance Acquisition Corp. |
02/14/2023 |
SC 13G/A
| Anson Funds Management LP reports a 0% stake in GO Acquisition Corp. |
02/14/2023 |
SC 13G/A
| Anson Funds Management LP reports a 0% stake in Equity Distribution Acquisition Corp. |
02/13/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/13/2023 |
3
| Anson Funds Management LP (10% Owner) has filed a Form 3 on Trilogy International Partners Inc. |
11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
|